> Bristol-Myers Squibb and Merck have formally ended a collaboration over the troubled diabetic therapy Pargluva. The FDA concluded last October that the drug needed further study before it could be approved. Report
> Nucryst Pharmaceuticals has priced its IPO of 4.5 million shares at $10 each. Report
> A 17-year federal study has concluded that tight control of blood sugar levels can reduce by half the risk of heart attacks and strokes among diabetics. Report
> Novavax of Malvern, PA has filed a shelf registration to sell up to $100 million in shares and securities. Release
> Toronto-based Vasogen has filed a shelf prospectus to sell up to $100 million in shares and securities. Release
> Cubist Pharmaceuticals has released new data from a Phase II study of HepeX-B, an experimental therapy to prevent reinfection with hepatitis B in patients with liver transplants. Release
> Large Scale Biology of Vacaville, CA has announced that its shares are subject to delisting from Nasdaq on December 27. The company is appealing the decision. Release
> Affymetric and Applied Biosystems have announced a licensing deal on the use of microarrays. Release
> SCOLR and Wyeth have executed a licensing agreement. Release
And Finally… Pfizer has outlined plans to grow in the Indian market. Report